CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells.
BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
干样T细胞可增强免疫治疗疗效,其干性具有异质性,其中长期(LT)干样T细胞处于层级顶端。目前尚不清楚嵌合抗原受体(CAR)T细胞的干性层级如何受到调控,以及这对抗肿瘤功能有何影响。本文显示,BACH2以剂量依赖方式调节CAR-T 细胞向LT干样状态分化及其抗肿瘤免疫。输注前出现并在肿瘤清除后再次出现的LT干样CAR-T 细胞,抗肿瘤免疫能力更强且BACH2表达最高。在CAR-T 细胞中,BACH2可促进抗肿瘤应答和LT干样转录程序。在制备过程中利用化学开关对BACH2表达进行定时、定量诱导,可精细调节细胞干性,并赋予其更强的实体瘤控制能力。总之,这些数据表明,BACH2水平决定CAR-T 细胞干性层级,且可通过时间和剂量调控来优化分化状态及抗肿瘤疗效。
Stem-like T cells promote the efficacy of immunotherapy and are heterogeneous in stemness, with long-term (LT) stem-like T cells at the apex of this hierarchy. How the stemness hierarchy is regulated in chimeric antigen receptor (CAR) T cells and how it affects antitumor function are unclear.
Here we show that BACH2 dose-dependently regulates LT stem-like differentiation and antitumor immunity of CAR T cells. LT stem-like CAR T cells that appear before infusion and re-emerge after tumor clearance have superior antitumor immunity and the greatest BACH2 expression.
BACH2 promotes the antitumor response of CAR T cells and the LT stem-like transcriptional program. Temporal and quantitative induction of BACH2 expression in CAR T cells during manufacturing using chemical switches fine-tunes the degree of stemness and imprints greater control of solid tumors.
Together, these data show that BACH2 dosage defines stemness hierarchy in CAR T cells and can be temporally and tunably controlled to optimize differentiation and antitumor efficacy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。